PB Handbook for Psychiatric Trainees
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

Psychiatric Bulletin (2001) 25: 378-381. doi: 10.1192/pb.25.10.378
© 2001 The Royal College of Psychiatrists
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stallard, J.
Right arrow Articles by Joyce, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stallard, J.
Right arrow Articles by Joyce, E.
Psychiatric Bulletin (2001) 25: 378-381
© 2001 The Royal College of Psychiatrists

The impact of olanzapine on attitude to medication and quality of life in schizophrenia

James Stallard, Specialist Registrar

Brent, Kensington, Chelsea and Westminster Mental Health NHS Trust

Eileen Joyce, Reader in General Psychiatry

Imperial College School of Medicine, Charing Cross Campus, St Dunstan's Road, London W6 8RP


   Abstract
Top
 Abstract
Introduction
 Method
 Findings
 Comment
 References
 
AIMS AND METHOD

This study aimed to compare the subjective quality of life and attitudes to medication between groups of patients with schizophrenia taking either olanzapine or traditional antipsychotic medication.

RESULTS

The two groups were matched for age, gender, length of illness and antipsychotic group demonstrated more extrapyramidal side-effects (EPS) and akathisia. Within this group, those with EPS scored lower on the affect balance scale of the Lancashire Quality of Life Scale than those without. More patients in the olanzapine group reported that medication was taken to prevent symptoms returning.

CLINICAL IMPLICATIONS

These results lend support to the hypothesis that the presence of EPS impairs quality of life and suggest that olanzapine therapy may improve patients' attitudes to medication.


   Introduction
Top
 Abstract
 Introduction
Method
 Findings
 Comment
 References
 
Poor rates of compliance are a problem for the treatment of schizophrenia and have been estimated to be between 11% and 80% (Kane, 1989). One of the many possible factors that can influence compliance is adverse medication effects and reduction of these may have a favourable effect on compliance rates (Barnes, 1989).

Since the reintroduction of clozapine (Kane et al, 1988), a number of antipsychotic drugs have been produced that attempt to mimic its pharmacological profile - the so-called ‘atypical’ antipsychotic agents. One such compound is olanzapine. This drug has been shown in several large trials to be as efficacious at controlling the symptoms of schizophrenia as haloperidol, but not to differ from placebo in incidence of extrapyramidal side-effects (EPS) (Beasley et al, 1996a, b, 1997; Tollefson et al, 1997). Whether the greater tolerability of such atypical drugs translates into better compliance has yet to be shown.

This study aimed to compare the attitude to medication of two groups of patients with schizophrenia, one taking olanzapine and another taking traditional antipsychotic medications. The hypothesis was that the greater tolerability of olanzapine owing to a lower incidence of EPS would lead to an improved attitude to medication in the olanzapine group. In addition, subjective quality of life in the two groups was assessed anticipating that decreased EPS in the olanzapine group would also result in better quality of life.


   Method
Top
 Abstract
 Introduction
 Method
Findings
 Comment
 References
 
All patients were recruited from acute adult services at South Kensington and Chelsea Mental Health Centre, London. Two groups of patients with a clinical diagnosis of schizophrenia were studied. These were 20 patients (five in-patients, 15 out-patients) receiving between 10 mg and 20 mg of olanzapine and 20 patients receiving depot traditional antipsychotic medication. All patients had been receiving their respective treatment for at least 6 weeks prior to entering the study. Patients were excluded if they were receiving any other psychotropic medication or if they were considered, on clinical grounds, to have been non-compliant in the 6 weeks prior to interview. Anticholinergic medication was not an exclusion factor.

For each subject, the following data were collected: age, gender, length of illness in years and length of time on medication in weeks. The following rating scales for assessing symptoms and side-effects were used: Clinical Global Impressions - Severity of Illness Scale (Guy, 1976), the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962), the Simpson-Angus Scale for EPS (Simpson & Angus, 1970) and the Barnes Akathisia Rating Scale (BARS; Barnes, 1989). In addition, the Rating of Medication Influences in Schizophrenia (ROMI; Weiden et al, 1994) and the Lancashire Quality of Life Profile (LQOLP, Oliver, 1991) were administered. The ROMI is a scale designed to explore attitudes to medication, which underpin compliance and non-compliance. The LQOLP is a scale that measures quality of life in each of nine domains and also contains three general sub-scales for global well-being, affect balance and self-concept.

Groups were compared using non-parametric statistical tests (SPSS statistical package). Data on a nominal scale were compared using the Chi-square ({chi}2) test. Data on ordinal or interval scales were analysed using the Mann-Whitney U Test. Correlations were calculated using Spearman's test.


   Findings
Top
 Abstract
 Introduction
 Method
 Findings
Comment
 References
 
As can be seen in Table 1, the two groups were well matched for age, gender, length of illness, severity of illness and psychopathology (using the BPRS). Accurate data on length of treatment were available for all patients in the olanzapine group and for 11 in the traditional antipsychotic group; this was significantly longer in the latter group.


View this table:
[in this window]
[in a new window]
  		Table 1. Group characteristics
 

Table 2 shows that significantly more patients receiving traditional antipsychotic medication demonstrated EPS than those receiving olanzapine. In addition, akathisia was more prominent in the traditional antipsychotic group than in the olanzapine group (using the BARS).


View this table:
[in this window]
[in a new window]
  		Table 2. Medication side-effects
 

There were no significant differences between the two groups with respect to the global quality of life scores: affect balance, self concept and global well-being; or for the nine more specific domains (range of Mann-Whitney Us=137.5-198.5, NS). To examine whether quality of life might be related to EPS in the traditional antipsychotic group, the global quality of life scores were compared for those with (n=8) and without (n=12) EPS. While there was no significant difference between the groups for self concept (Mann-Whitney U=35, NS) or global well-being (Mann-Whitney U=33.5, NS), the EPS group scored significantly lower on the affect balance scale (Mann-Whitney U=21, P<0.05).

On the ROMI, patients were shown seven statements that might reflect reasons for compliance and 13 for non-compliance, and were required to indicate the level of agreement between each statement and their own attitude to medication with the aid of a three-point scale: strong, mild, none. More patients in the olanzapine group agreed with the statement that they were taking their medication because they felt it stopped their symptoms returning (85% v. 55%, {chi}2=3.903, P<0.05). There were no differences for the remaining statements (range of {chi}2=0.04-1.71, NS). Following Weiden (1991), the seven compliance factors were collapsed into broader reasons: medication affinity, influence of others and prevention. Table 3 shows that there was no difference between the two groups for the former two factors. However, significantly more patients receiving olanzapine scored full marks for the ‘prevention’ factor. There was no significant difference between the groups for any of the non-compliance factors. However, there was a trend for more patients on traditional depot antipsychotic medication to cite "embarrassment about taking medication" as a reason for potential non-compliance (90% v. 65%, {chi}2=3.584, P=0.058).


View this table:
[in this window]
[in a new window]
  		Table 3. Rating of medications influence (ROMI): collapsed factors for compliance
 


   Comment
Top
 Abstract
 Introduction
 Method
 Findings
 Comment
References
 
No significant difference was found between the two groups with respect to subjective quality of life measures. However, within the traditional antipsychotic group presence of EPS was found to be related to lower affect balance scores. In the LQOLP, the affect balance and self concept scales can be seen as measuring mood and morale, respectively. Both have been shown to influence quality of life outcomes in patients with severe mental illness (Oliver, 1991).

More patients taking olanzapine said that they were compliant because they felt their medication stopped their symptoms returning. At the same time there was a trend for patients taking traditional antipsychotics to cite "embarrassment about taking medication" as a potential reason for non-compliance. The reasons for this difference in attitude between the groups are not clear. It may be owing in part to the route of administration rather than the medication itself. The patients were receiving traditional antipsychotic medication in depot form, which might be less acceptable than oral medication for several reasons. These include the need for more frequent contact with services and perceived loss of dignity. Receiving depot medication may also cause physical problems such as painful injection sites. The ‘embarrassment’ cited could also be related to motor dysfunction experienced owing to EPS or akathisia.

Some authors, however, have hinted that improvements in attitude to medication in patients taking olanzapine may be related to more subtle intra-psychic factors. Beasley et al (1996b) found an improvement in quality of life in patients with schizophrenia and that this appeared to be owing to an impact on intra-psychic foundations, a sense of purpose, motivation and emotional interaction. Conversely, although data regarding weight gain in patients taking olanzapine were not available, significant weight gain may have resulted in a negative impact on attitude to medication.

This study provides indirect support for the hypothesis that reduced EPS in patients receiving olanzapine may improve quality of life. However, as patients receiving traditional drugs had been treated for longer than those receiving olanzapine, it is possible that prolonged treatment with olanzapine may also lead to increased rates of EPS with an adverse impact on quality of life. Further, an emerging adverse effect in patients receiving olanzapine is weight gain, which was not assessed in this study. It is possible that this may contribute to self-assessed quality of life in the same way as EPS in those receiving traditional drugs. The study also showed an improvement in attitude to medications in patients taking olanzapine. The reasons for this change in attitude, however, remain unclear. A clear link between the greater tolerability of atypical medications and better compliance rates has yet to be shown, but this study suggests that olanzapine and the newer atypicals represent an advance in the drug treatment of schizophrenia and one that may lead to greater patient satisfaction and, therefore, compliance.


   References
Top
 Abstract
 Introduction
 Method
 Findings
 Comment
 References
 
BARNES, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.[Abstract/Free Full Text]

BEASLEY, C., SANGER, T., SATTERLEE, W., et al (1996a) Results of a double-blind fixed-dose olanzapine trial. Psychopharmacology, 124, 159-167.[CrossRef][Medline]

BEASLEY, C., TOLLEFSON, G., TRAN, P., et al (1996b) Olanzapine versus haloperidol and placebo: acute phase results of North American olanzapine trial. Neuropsychopharmacology, 14, 111-124.[CrossRef][Medline]

BEASLEY, C., HAMILTON, S., CRAWFORD, A., et al (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125-137.[CrossRef][Medline]

GUY, W. (1976) ECDEU Assessment Manual for Psychophamarcology. Revised DHEW Pub (ADM). Rockville, MD: National Institute of Mental Health.

KANE, J. (1989) The current status of neuroleptics. Journal of Clinical Psychiatry, 50, 322-328.[Medline]

KANE, J., HONINGFIELD, G., SINGER, J., et al (1988) Clozapine in treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.[Abstract]

OLIVER, J. (1991) The social care directive: development of a quality of life profile for use in community services for the mentally ill. Social Work and Social Sciences Review, 3, 5-45.

OVERALL, J. & GORHAM, D. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.

SIMPSON, G. & ANGUS, J. (1970) A Rating Scale for Extrapyramidal Symptoms. Acta Psychologica Scandinavica, 212, 511-519.

TOLLEFSON, G., BEASLEY, C., TRAN, P., et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 466-474.[Abstract]

WEIDEN, P. (1991) Neuroleptic non-compliance in schizophrenia. In: Advances in Neuropsychiatry and Psychopharmacology: Schizophrenia Research (eds C. Tamminga & S. Schultz), pp. 285-299. New York: Raven Press.

WEIDEN, P. RAPKIN, B., MATT, T., et al (1994) Rating of Medication Influences (ROMI) Scale in schizophrenia. Schizophrenia Bulletin, 20, 297-310.





This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stallard, J.
Right arrow Articles by Joyce, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stallard, J.
Right arrow Articles by Joyce, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals